Precision-engineered instrumentation driving high-throughput liquid biopsy workflows and molecular assay execution.
Shenzhen BioX Medical Co., Ltd. stands as a premier manufacturer and exporter specializing in high-throughput molecular diagnostic analysis systems, liquid biopsy enrichment technologies, genetic testing solutions, and advanced clinical laboratory instrumentation. Established in 2017, the enterprise is headquartered in Shenzhen, China—a global nexus for biotechnology research, high-precision medical device engineering, and automated diagnostic device manufacturing.
With an expansive, modern manufacturing facility spanning over 9,000 square meters and an expert workforce exceeding 200 dedicated professionals, BioX Medical integrates basic biomarker research, mechanical engineering, microfluidics design, and automated instrument assembly under rigorous international quality management systems (ISO 13485). Our enterprise is dedicated to delivering clinical-grade liquid biopsy platforms, automated nucleic acid extraction systems, real-time PCR instrumentation, and precision assay consumables to clinical laboratories, academic research institutes, public health organizations, and biotechnology OEMs across North America, Europe, Asia-Pacific, the Middle East, Latin America, and Africa.
The company's product portfolio encompasses state-of-the-art molecular diagnostic platforms, targeted liquid biopsy circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) enrichment workflows, automated gel documentation hardware, real-time quantitative PCR (qPCR) platforms, ultrasound diagnostic systems, and specialized bio-bank sample preservation infrastructure (such as ultra-fast nitrogen liquefiers). By seamlessly unifying mechanical automation, optical sensing, and cloud-compatible bioinformatic data management, BioX Medical builds complete analytical ecosystems engineered to maximize assay sensitivity, minimize manual intervention, and elevate diagnostic accuracy.
Analyzing the paradigm shift from invasive tissue biopsies to real-time circulating biomarker profiling in precision oncology and genetic disease management.
Circulating tumor DNA (ctDNA) fragments carry crucial somatic mutation signatures, copy number variations (CNVs), and epigenetic methylation patterns. Standardized automated isolation methods prevent sample degradation and optimize recovery from ultra-low concentrations (down to sub-nanogram levels per mL of plasma).
Intact CTC capture offers unprecedented insights into tumor heterogeneity, gene expression, single-cell genomics, and functional drug sensitivity assays. Modern microfluidic and immuno-affinity sorting systems enable gentle CTC isolation with high viability for downstream multi-omics analysis.
Exosomes encapsulating regulatory microRNAs, long non-coding RNAs, and functional proteins act as biological messengers. Advanced size-exclusion and membrane-based isolation protocols yield pristine extracellular vesicle fractions essential for early-stage disease profiling.
Compared with traditional tissue biopsy—which suffers from surgical invasiveness, procedural risks, sampling bias, and an inability to track longitudinal tumor dynamics—liquid biopsy technologies enable real-time, non-invasive molecular profiling. By capturing peripheral blood samples (or urine, CSF, and pleural fluids), clinicians can continuously monitor Minimal Residual Disease (MRD), detect therapeutic resistance mechanisms early, and tailor targeted treatments for precision medicine initiatives.
The successful clinical translation of liquid biopsy platforms relies heavily on selecting the correct detection method, balancing limit of detection (LOD), throughput, cost-efficiency, and bioinformatic requirements. BioX Medical manufactures specialized instrumentation designed to seamlessly support diverse analytical approaches:
| Analytical Technology | Target Biomarkers | Sensitivity (LOD) | Throughput / Multiplexing | Primary Clinical Applications |
|---|---|---|---|---|
| Digital PCR (dPCR) | Targeted Point Mutations (ctDNA), CNVs | Ultra-High (< 0.01% VAF) | Low to Moderate (1 - 6 targets) | MRD Tracking, Known Resistance Mutation Screening (e.g., EGFR T790M) |
| Real-Time qPCR (e.g., Gentier96E) | Targeted DNA/RNA, HPV Genotyping, Pathogens | High (< 0.1% VAF) | Moderate (4 - 6 Channels) | Pathogen Detection, Companion Diagnostics, HPV Profiling |
| Targeted NGS Panels | Multi-gene SNVs, Indels, Fusions, Methylation | High (0.1% - 0.5% VAF) | Ultra-High (10s to 100s of Genes) | Multi-Cancer Early Detection (MCED), Therapy Selection |
| Immuno-Microfluidic CTC Capture | Whole Intact Circulating Cells | Single-cell Sensitivity | Targeted Cell Isolation | Single-cell RNA-seq, Functional Phenotyping, Organoid Culture |
Liquid biopsy extraction methods require robust protection against genomic DNA (gDNA) contamination from lysed white blood cells. Shenzhen BioX Medical's integrated extraction workflows maintain cell membrane stability during cell-free plasma collection, ensuring pure ctDNA enrichment for error-free qPCR and NGS library preparation.
Global diagnostic distributors, clinical contract research organizations (CROs), hospital networks, and molecular reagent manufacturers face stringent procurement standards when sourcing diagnostic instrumentation from China. BioX Medical bridges high-tech innovation with cost-efficient scalability, presenting a comprehensive enterprise OEM/ODM supply framework.
Through flexible OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) partnerships, BioX Medical offers customized firmware development, industrial design tailoring, private labeling, and custom optical channel calibration tailored to specific geographic markets and assay protocols.
Empowering medical laboratories, veterinary clinics, material science centers, and industrial testing networks with robust analytical systems.
Integrating qPCR thermal cyclers, gel documentation units, and high-sensitivity optical detectors to support liquid biopsy mutation profiling, tumor burden tracking, and non-invasive cancer screening initiatives.
Portable and desktop multi-channel fluorescence PCR analyzers customized for rapid viral and bacterial detection, livestock health management, and localized epidemiological surveillance.
Extending laboratory precision to non-medical sectors, including cross-sectional crimp analysis, 3D precision welding platforms, and specialized mineral spectroscopy for structural and metallurgical assurance.
Reliability forms the cornerstone of clinical diagnostic technology. Shenzhen BioX Medical Co., Ltd. enforces a multi-stage quality assurance protocol across the entire production lifecycle within its 9,000 m² facility.
Every piece of diagnostic equipment—from real-time PCR units to full-digital ultrasound diagnostic stations—undergoes environmental stress screening (ESS), thermal cycling precision validation, optical sensitivity calibration, and automated software diagnostics prior to packaging. Components are sourced from audited Tier-1 global vendors to ensure zero compromise on operational life.
Our instruments are designed and manufactured under ISO 13485 quality management systems for medical devices. Product lines comply with European Union CE-IVD directives, electromagnetic compatibility standards (EMC), and relevant electrical safety benchmarks, supporting seamless regulatory filings for local importers in over 60 countries.
To ensure continuous clinical operations, BioX Medical provides overseas technical training, remote diagnostic engineering support, spare-parts supply guarantees, and comprehensive multi-language operational documentation. Diagnostic laboratories and distributors receive direct access to our senior field application specialists.
Driving the frontier of AI-enhanced liquid biopsy interpretation, automated single-cell multi-omics, and point-of-care microfluidics.
Integrating artificial intelligence algorithms directly into quantitative PCR and sequencing workflow software to automatically filter background noise, resolve ultra-low VAF signals, and present real-time clinical decision support.
Combining CTC sorting, single-cell genomics, epigenomics, and transcriptomics into automated cartridges, eliminating fluid loss and delivering holistic tumor evolution mapping.
Miniaturizing liquid biopsy extraction and dPCR amplification into self-contained microfluidic discs, reducing turnaround time (TAT) from days to under 60 minutes for near-patient testing.
Expert answers addressing sample preparation, analytical sensitivity, OEM collaboration, and regulatory compliance.
A glimpse inside our 9,000+ m² modern facility, automated assembly lines, cleanrooms, and testing infrastructure in Shenzhen.
Complete your diagnostic infrastructure with our specialized characterization systems, ultrasound platforms, and qPCR arrays.
BioX Medical